Načítá se...
Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab
Pembrolizumab is a programmed cell death protein 1 (PD-1) monoclonal antibody used in the treatment of metastatic melanomas. Severe ocular complications appear in less than 1% of the patients and require early treatment. We present the case of a patient diagnosed with a BRAF mutated metastatic melan...
Uloženo v:
| Vydáno v: | Indian J Ophthalmol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer - Medknow
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6896544/ https://ncbi.nlm.nih.gov/pubmed/31755465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijo.IJO_1161_19 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|